| cyclophosphamide / Generic mfg. |
| Recruiting | N/A | 180 | RoW | Prednisone, Vincristin, Daunorubicin, Peg-asparaginase, Intrathecal Suspension, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin | Instituto do Cancer do Estado de São Paulo, Servier | Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality, Chemotherapeutic Toxicity | 06/28 | 06/30 | | |
| Recruiting | N/A | 150 | Europe | blood sample | Centre Georges Francois Leclerc | Breast Cancer | 05/30 | 05/30 | | |
NCT04160390: Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant |
|
|
| Recruiting | N/A | 60 | US | Biospecimen Collection-Blood, Biospecimen Collection-Stool | City of Hope Medical Center, National Cancer Institute (NCI) | Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm | 04/27 | 04/27 | | |
| Recruiting | N/A | 500 | Europe | | Vifor Fresenius Medical Care Renal Pharma | ANCA-associated Vasculitis | 12/30 | 12/30 | | |
NCT02161783: Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | N/A | 50 | US | Fludarabine, Fludara, Cyclophosphamide, Total Body Irradiation, TBI, Hematopoietic stem cell infusion, HSCT | Masonic Cancer Center, University of Minnesota | Primary Graft Failure, Secondary Graft Failure | 01/32 | 01/32 | | |
NCT03555851: Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy |
|
|
| Recruiting | N/A | 120 | US | Cyclophosphamide, Specimen collection | Wake Forest University Health Sciences, Atrium Health Levine Cancer Institute | Leukemia, Not Otherwise Specified, Leukemia, Other | 10/33 | 08/35 | | |
NCT00683319: Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy |
|
|
| Active, not recruiting | N/A | 50 | Europe | carboplatin, cisplatin, cyclophosphamide, methotrexate, vincristine sulfate, adjuvant therapy, cognitive assessment, magnetic resonance imaging, magnetic resonance spectroscopic imaging, quality-of-life assessment | Children's Cancer and Leukaemia Group | Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Ototoxicity | 03/34 | | | |
